Is There Any Possibility of Uterine Sarcoma, STUMP and Benign Myoma Variants in the Patients Operated for Myoma Uteri

Abstract

Malignant pathologies may be observed in the histopathological examination of the patients who were operated with the diagnosis of myoma uteri. We aimed to to investigate the rates of detection of uterine sarcoma, smooth muscle tumor of uncertain malignant potential and benign myoma variants who were operated due to myoma uteri. Patients who were operated with the diagnosis of myoma uteri between 2012-2018 were included. Patients with and without malignant pathology were compared in terms of their characteristics. The malignancy was encountered in 39 patients (1.5%) among 2583 patients. A significant difference was found between the patients with and without malignancy in terms of age, admission complaints, and cervical smear results. Patients in the malignant group were found to be older (52.5±11.0 vs 48.1±6.1, p=0.016). Postmenopausal bleeding was significantly a more common complaint in the malignant group (p=0.028). The rate of abnormal cytology in the cervical smear results in the malignant group was 5.1% (p=0.004). Pathology reports of the patients who were operated for myoma uteri may result with malignancy. In the preoperative evaluation, it is necessary to pay attention to the patients’ characteristics, to evaluate the risk factors for the possibility of a malignancy.

Keywords

• hysterectomy
• myoma uteri
• uterine sarcoma
• myomectomy
• STUMP (smooth muscle tumor of uncertain malignant potential)

References

1. 1. Augusto KL, Brilhante AVM, Modesto GCD, Saboia DM, Rocha CFC, Karbage SAL, et al. Costs and mortality rates of surgical approaches to hysterectomy in Brazil. Rev Saude Publica 2018; 52: 25.
2. 2. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188:100.
3. 3. Berisavac M, Sparic R, Argirovic R. Contraception: modern trends and controversies. Srp Arh Celok Lek. 2009;137(5-6):310–319.
4. 4. Christacos NC, Quade BJ, Dal Cin P, Morton CC. Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features. Genes Chromosomes Cancer 2006; 45:304.
5. 5. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990;94(4):435–438.
6. 6. D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010; 116:131–139.
7. 7. Dinh TA, Oliva EA, Fuller AF Jr, Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol Oncol 2004; 92:648.
8. 8. Evans P, Brunsell S. Uterine fibroid tumors: diagnosis and treatment. Am Fam Physician. 2007;75(10):1503–1508.

9. 9. Felix AS, Cook LS, Gaudet MM, Rohan TE, Schouten LJ, Setiawan VW, et al. The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium. Br J Cancer. 2013;108(3):727–734.
10. 10. Fleischer R, Weston GC, Vollenhoven BJ, Rogers PA. Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):603–614.
11. 11. He Y, Zeng Q, Li X, Liu B, Wang P. The association between subclinical atherosclerosis and uterine fibroids. PLoS One. 2013;8(2):e57089–e57089.
12. 12. Hodge JC, Morton CC. Genetic heterogeneity among uterine leiomyomata: insights into malignant progression. Hum Mol Genet 2007; 16 Spec No 1:R7.
13. 13. Hodge JC, Pearce KE, Clayton AC, Taran FA, Stewart EA. Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. Am J Obstet Gynecol 2014; 210:572.e1.
14. 14. Jin Y, Pan L, Wang X, Dai Z, Huang H, Guo L, et al. Clinical characteristics of endometrial stromal sarcoma from an academic medical hospital in China. Int J Gynecol Cancer 2010; 20:1535.
15. 15. Kapp D S, Shin J Y, Chan J K. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112:820–830.
16. 16. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70:432.
17. 17. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):571–588.
18. 18. Parazzini F, La Vecchia C, Negri E, Cecchetti G, Fedele L. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol 1988; 72:853.
19. 19. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007;87(4):725–736.
20. 20. Parker WH, Fu YS, Berek JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994; 83:414.
21. 21. Pritts E, Parker WH, Brow J, Olive DL. Outcome of occult uterine leiomyosarcoma after surgery for presumed uterine fibroids: a systematic review. J Min Invasive Gynecol. 2014;22(1):26–33.
22. 22. Pritts EA, Vanness DJ, Berek JS, Parker W, Feinberg R, Feinberg J, et al. The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecol Surg (2015) 12:165–177.
23. 23. Raine-Bennett T, Tucker LY, Zaritsky E, Littell RD, Palen T, Neugebauer R, et al. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation. Obstet Gynecol 2016; 127:29.
24. 24. Robboy SJ, Bentley RC, Butnor K, Anderson MC. Pathology and pathophysiology of uterine smooth-muscle tumors. Environ Health Perspect 2000; 108 Suppl 5:779.
25. 25. Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology 2004; 67:33.
26. 26. Schwartz LB, Diamond MP, Schwartz PE. Leiomyosarcomas: clinical presentation. Am J Obstet Gynecol 1993; 168:180.
27. 27. Sparic R, Hudelist G, Berisavac M, Gudovic A, Buzadzic S. Hysterectomy throughout history. Acta Chir Iugosl. 2011;58(4):9–14.
28. 28. Stein K, Ascher-Walsh C. A comprehensive approach to the treatment of uterine leiomyomata. Mt Sinai J Med. 2009; 76:546Y556.
29. 29. Stewart EA. Differentiating uterine leiomyomas (fibroids) from uterine sarcomas. UpToDate.
30. 30. Stewart EA, Morton CC. The genetics of uterine leiomyomata: what clinicians need to know. Obstet Gynecol 2006; 107:917.
31. 31. Taran FA, Weaver AL, Gostout BS, Stewart EA. Understanding cellular leiomyomas: a case-control study. Am J Obstet Gynecol 2010; 203:109.e1.
32. 32. Terry KL, De Vivo I, Hankinson SE, Missmer SA. Reproductive characteristics and risk of uterine leiomyomata. Fertil Steril. 2010;94(7):2703–2707.
33. 33. Uimari O, Suomalainen-Konig S, Sakkinen N, Santala M, Nieminen P, Ryynanen M. Natural history of familial myomas. Eur J Obstet Gynecol Reprod Biol. 2006;125(2):255–258.
34. 34. Wise LA, Laughlin-Tommaso SK. Uterine leiomyomata. In: Goldman MB, Troisi R, Rexrode KM, editors. Women and Health. San Diego: Academic Press; 2013. pp. 285–306.
35. 35. Wise LA, Palmer JR, Harlow BL, Spiegelman D, Stewart EA, Adams-Campbell LL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004; 159:113.
36. 36. Wright JD, Tergas AI, Burke WM, Cui RR, Ananth CV, Chen L, et al. Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation. JAMA 2014; 312:1253.